Key Takeaways
- • Archimed has completed the carve-out of Standard BioTools' microfluidics unit, which now operates as Biomark Scientific.
- • Under Archimed ownership, Biomark Scientific aims to expand its capabilities across genomics, clinical research and public health.
- • The transaction is categorized as a healthcare and life sciences deal in North America, according to PEI Private Equity.
Summary
Private equity firm Archimed has completed the carve-out of the microfluidics unit of Standard BioTools, the U.S.-listed life sciences tools company. The business now operates under the name Biomark Scientific, according to PEI Private Equity.
Following the separation, Biomark Scientific will pursue an expansion strategy under Archimed's ownership. The company intends to broaden its capabilities across genomics, clinical research and public health, markets where microfluidics technology is applied in areas such as high-throughput analysis and diagnostics.
The source article is a brief deal report and does not disclose the transaction value, financing structure or other financial terms.
Following the separation, Biomark Scientific will pursue an expansion strategy under Archimed's ownership. The company intends to broaden its capabilities across genomics, clinical research and public health, markets where microfluidics technology is applied in areas such as high-throughput analysis and diagnostics.
The source article is a brief deal report and does not disclose the transaction value, financing structure or other financial terms.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.